Photo taken from Mohammed Shahait/X
Jan 19, 2024, 19:10
Mohammed Shahait: Our new study “Termination of Urologic Cancer Trials”
Mohammed Shahait, Clinical Instructor of Urology at The University of Pennsylvania and The University of Pittsburgh Medical Center, shared on X/Twitter:
“Our new study “Termination of Urologic Cancer Trials” at JCO Global Oncology.
25% termination rate.
Main cause: Low patient accrual.
Risk factors: University funding, single-center, small sample.”
Additional information.
Source: Mohammed Shahait/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22